We hypothesize that: (1) ALPS index reduction specifically marks AD-stage pathology (Zhou et al., 2024); (2) Right-lateralized hippocampal mean diffusivity (MD) progression reflects tau-mediated asymmetric neurodegeneration; (3) Combined ALPS/MD metrics improve diagnostic accuracy beyond single-modality biomarkers. This evidence concerns the gene MAPT and Alzheimer disease.